Electronic Theses and Dissertations

Date of Award

1-1-2024

Document Type

Thesis

Degree Name

M.S. in Pharmaceutical Science

First Advisor

Michael A. Repka

Second Advisor

Eman Ashour

Third Advisor

Walter G. Chambliss

Relational Format

dissertation/thesis

Abstract

Simvastatin, a potent HMG-CoA reductase inhibitor, lowers cholesterol levels. It prevents cardiovascular events like heart attacks and strokes in patients with high cholesterol and heart disease. However, its oral bioavailability is limited due to its poor aqueous solubility The current study aims to enhance the solubility of the poorly water-soluble drug simvastatin through the development of self-emulsifying drug delivery systems (SEDDS). Gelucire® 48/16 (oil), Gelucire 44/14 (surfactant), and Cremophor RH40 (co-surfactant) were assessed as potential excipients for SEDDS formulation. Initial SEDDS (Before adsorption) formulations were created based on the solubility of simvastatin in solid lipid excipients, as determined by a method developed by Gattefossé. Subsequent optimization of these formulations was conducted based on In-vitro drug release studies. Lead formulations were transformed into granules of solid SEDDS (S-SEDDS) by adsorbing drug-lipid mixture onto solid carriers using the Twin Screw Granulation (TSG) approach. Interestingly, granules extruded with temperature exhibited improved drug release in dissolution studies. The lead formulations of both SEDDS (F7) and S-SEDDS (S5, S6) were evaluated for emulsification time, globule size, and polydispersity index (PDI). Additionally, the developed formulations were assessed for their solid-state properties using differential scanning calorimetry (DSC), revealing the drug's existence in an amorphous state. Fourier transform infrared spectroscopy (FTIR) confirmed drug-excipient compatibility and the absence of interactions. Moreover, the flow properties of the extruded granules were analyzed to further assess their suitability for drug delivery applications. Therefore, the developed SEDDS formulation could be an effective oral delivery platform for simvastatin and could lead to better therapeutic outcomes.

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.